Literature DB >> 2391399

Diphenhydramine: pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children.

K J Simons1, W T Watson, T J Martin, X Y Chen, F E Simons.   

Abstract

The pharmacokinetics and pharmacodynamics of the H1-receptor antagonist diphenhydramine were studied in 21 fasting subjects divided into three age groups: elderly, (mean age 69.4 +/- 4.3 years), young adults, (mean age 31.5 +/- 10.4 years), and children, (mean age 8.9 +/- 1.7 years). All subjects ingested a single dose of diphenhydramine syrup 1.25 mg/kg, in mean doses of 86.0 +/- 7.3 mg, 87.9 +/- 12.4 mg, and 39.5 +/- 8.4 mg, respectively. Blood samples were collected hourly for 6 hours, every 2 hours until 12 hours, at 24 hours, and, in the adults, up to 72 hours after diphenhydramine administration. At these times, histamine skin tests were performed and wheal and flare areas were computed. The mean serum elimination half-life values for diphenhydramine differed significantly in elderly adults, young adults, and children, with values of 13.5 +/- 4.2 hours, 9.2 +/- 2.5 hours, and 5.4 +/- 1.8 hours being found respectively in each age group. Clearance rates for diphenhydramine also differed significantly with age, being 11.7 +/- 3.1 mL/min/kg in elderly adults, 23.3 +/- 9.4 mL/min/kg in young adults and 49.2 +/- 22.8 mL/min/kg in children. Diphenhydramine produced a maximum wheal suppression of 39.6 +/- 22.5% and a maximum flare suppression of 46.5 +/- 32.1% at 5 and 6 hours respectively in the elderly; a maximum wheal suppression of 45.5 +/- 25.0% and a maximum flare suppression of 53.4 +/- 16.9% at 6 and 4 hours respectively in young adults; and a maximum wheal suppression of 68.4 +/- 10.2% and a maximum flare suppression of 87.2 +/- 4.2% at 2 hours in children.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2391399     DOI: 10.1002/j.1552-4604.1990.tb01871.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  21 in total

Review 1.  Pharmacokinetic optimisation of antiemetic therapy.

Authors:  M Campbell; D N Bateman
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

2.  Survival after diphenhydramine ingestion with hemodialysis in a toddler.

Authors:  Nathanael J McKeown; Patrick L West; Robert G Hendrickson; B Zane Horowitz
Journal:  J Med Toxicol       Date:  2011-06

3.  Sleep Health and Appropriate Use of OTC Sleep Aids in Older Adults-Recommendations of a Gerontological Society of America Workgroup.

Authors:  Steven M Albert; Thomas Roth; Michael Toscani; Michael V Vitiello; Phyllis Zee
Journal:  Gerontologist       Date:  2015-10-28

4.  Effect of cimetidine on the pharmacokinetics and pharmacodynamics of chlorpheniramine and diphenhydramine in rabbits.

Authors:  K J Simons; X Chen; T G Fraser; F E Simons
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

5.  Over-the-Counter Agents for the Treatment of Occasional Disturbed Sleep or Transient Insomnia: A Systematic Review of Efficacy and Safety.

Authors:  Larry Culpepper; Mark A Wingertzahn
Journal:  Prim Care Companion CNS Disord       Date:  2015-12-31

Review 6.  Pharmacokinetic optimisation of histamine H1-receptor antagonist therapy.

Authors:  F E Simons; K J Simons
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

7.  Disulfiram-like Reaction Involving Ceftriaxone in a Pediatric Patient.

Authors:  Stephen M Small; Rachel S Bacher; Sheridan A Jost
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Mar-Apr

Review 8.  Drug dosage in the elderly. Is it rational?

Authors:  K Turnheim
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 3.923

9.  Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers.

Authors:  J M Gandon; H Allain
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

10.  Knowledge of developmental pharmacology and modeling approaches should be used to avoid useless trials in children.

Authors:  Saskia N de Wildt; Catherijne A J Knibbe
Journal:  Eur J Clin Pharmacol       Date:  2009-04-25       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.